Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.
Frank A. Sinicrope, MD
Advertisement
Articles by Frank A. Sinicrope, MD
Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer
Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.
Advertisement
Latest Updated Articles
Dr Sinicrope on the Efficacy and Safety of mFOLFOX6 Plus Atezolizumab in Stage III dMMR CRCPublished: July 10th 2025 | Updated:
Dr. Sinicrope on Mismatch Repair-Deficient Patients With Metastatic Colorectal CancerPublished: September 1st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5